1,797 reports of this reaction
4.1% of all CLOBAZAM reports
#4 most reported adverse reaction
SOMNOLENCE is the #4 most commonly reported adverse reaction for CLOBAZAM, manufactured by Lundbeck Pharmaceuticals LLC. There are 1,797 FDA adverse event reports linking CLOBAZAM to SOMNOLENCE. This represents approximately 4.1% of all 43,741 adverse event reports for this drug.
Patients taking CLOBAZAM who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is moderately reported among CLOBAZAM users, representing a notable but not dominant share of adverse events.
In addition to somnolence, the following adverse reactions have been reported for CLOBAZAM:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 1,797 FDA reports for CLOBAZAM. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 4.1% of all adverse event reports for CLOBAZAM, making it a notable side effect.
If you experience somnolence while taking CLOBAZAM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.